imetelstat

Geron Corporation (NASDAQ: GERN), which is given to volatility due to heavy short interest, made a wild swing to the downside Thursday. What Happened Geron announced ahead of the market open that Johnson & Johnson (NYSE: JNJ)'s Janssen unit has decided to terminate a...

Geron Corporation (NASDAQ: GERN) stock is popping Friday without any major news from the company. Traders are speculating the huge jump in share price may have to do with a simple job posting. Geron's stock was trading up 27 percent to $5.13 at time of publication. What Happened? On Friday...

Shares of Geron Corporation (NASDAQ: GERN) were trading at $2.08 Wednesday morning and are within two cents of its 52-week low of $2.06. Investors punished the stock on Monday after the bio-pharmaceutical company announced an update from a clinical trial involving Imetelstat, a potent and specific...

BTIG expects Geron Corporation (NASDAQ: GERN) shares to be range-bound until major data release, potentially in late 2017 or 2018. Geron's lead compound imetelstat, an inhibitor of telomerase partnered with Johnson & Johnson (NYSE: JNJ)'s Janssen showed impressive activity in multiple...

U.S. stocks were little changed as investors found no new positive (or negative) developments from Ukraine and no new economic reports from China. Stanley Fischer, the nominee for Federal Reserve vice chairman will deliver a prepared testimony ahead of his confirmation at the Senate Banking...